Vinayaka Mission's Research Foundation is a UGC, Government of India recognized private deemed-to-be-university located in Salem, Tamil Nadu, India. In 2015, the University was accredited by National Assessment and Accreditation Council.
Underwater Friction Stir Welding has arisen as proficient solid-state joining method for aluminium alloys necessitating stringent heat regulation. This work experimentally tested and systematically optimized the mechanical performance of 5 mm thick AA5754 butt joints produced by Underwater Friction Stir Welding. The influence of tool rotational speed, axial force and welding speed, on microhardness and tensile strength was assessed by an experimental design based on Taguchi orthogonal array. ANOVA were utilized to assess significance and impact of each process parameter. A multi-criteria decision-making (MCDM) MEREC and CoCoSo approaches was employed to determine best parameter combination, thereby addressing constraints of traditional single-response optimization. The findings indicate that tool rotational speed is the predominant contributor, succeeded by axial force and welding speed. Ideal process parameters for enhanced ki was determined at a a tool rotation speed of 1100 rpm, an axial force of 6 kN, and welding speed of 20 mm/min, corresponding to (X2 Y2 Z2). The enhanced UFSW condition led to a significant enhancement in joint efficiency and tensile strength, achieving approximately 90
The utilization of fiber-reinforced composite materials is increasingly prevalent in the aerospace, structural and automotive industries, owing to lightweight characteristics. This research evaluates tamarind seed shell powder (TSSP) reinforced Waru bark-Banana pseudostem (WBBP) fiber composites, fabricated using compression molding. TSSP was incorporated at weight ratios of 0, 2, 4, 6, and 8 wt
Oral squamous cell carcinoma (OSCC) is a significant global health concern, with approximately 377,000 new cases diagnosed annually worldwide. Despite advances in treatment, OSCC remains a leading cause of cancer-related morbidity and mortality, particularly in regions with high prevalence such as Asia and Oceania. In order to identify potential drug targets for OSCC, this study employed an integrative in silico pharmacology strategy. Nineteen GEO transcriptomic datasets (435 samples) were analyzed, 580 significantly overexpressed genes (logFC > 2.5). Network and enrichment analyses highlighted CASQ1 (calsequestrin 1), a calcium-binding protein, as a hub gene within a sarcomeric cluster implicated in epithelial–mesenchymal transition and OSCC progression. To explore its therapeutic potential, molecular docking and 500 ns molecular dynamics (MD) simulations were performed with standard chemotherapeutics, 5-fluorouracil and docetaxel. 5-fluorouracil exhibited strong binding affinity (− 7.225 kcal/mol) and stable conformational dynamics with CASQ1, while docetaxel showed more flexible but persistent binding. These results suggest that CASQ1 is a previously unrecognized drug-interactable target in OSCC and may represent a novel pharmacological vulnerability. Overall, this study demonstrates how integrative computational approaches, spanning gene expression profiling to drug–target interaction modeling, can accelerate target discovery and inform therapeutic strategies in oncology.
Background: Ischemic cardiomyopathy remains a leading cause of cardiovascular mortality. Autologous CD133 + therapy has emerged as a promising alternative for ischemic cardiomyopathy in patients undergoing coronary artery bypass grafting (CABG). However, evidence regarding its safety and clinical efficacy remains limited, restricting the ability to clearly define its therapeutic role in ischemic cardiomyopathy. This uncertainty underscores the need for a systematic evaluation of the available evidence. Therefore, this systematic review and meta-analysis aimed to evaluate the clinical efficacy and safety of adjunctive CD133 + stem cell therapy administered during CABG. Methods: A comprehensive search of PubMed, Embase, Web of Science, Scopus, Google Scholar, and Cochrane databases was conducted from inception to January 2026. Eligible studies included English-language randomized controlled trials (RCTs) and observational studies involving adults (≥18 years) with ischemic cardiomyopathy undergoing CABG in whom intraoperative administration of autologous CD133 + cells plus CABG was compared with CABG alone. Results: 11 studies and 495 participants were included in the analysis. Compared with coronary artery bypass grafting (CABG) alone, adjunctive CD133 + cell therapy was not associated with significant differences in magnetic resonance imaging (MRI)-derived left ventricular ejection fraction (LVEF) (n=144; mean difference [MD], 0.40 [95% CI, –5.60 to 6.41]; p=0.89; I 2 =72.9%), MRI-assessed myocardial scar burden (n=86; MD, –1.94 [95% CI, –8.17 to 4.28]; p=0.54; I 2 =0%), or ultrasound-derived LVEF (n=278; MD, 0.45 [95% CI, –2.24 to 3.14]; p=0.74; I 2 =45.3%). No significant differences were observed in arrhythmia (n=118; relative risk [RR], 1.00 [95% CI, 0.85-1.19]; p=0.87; I 2 =0%) or mortality (n=114; RR, 1.31 [95% CI, 0.06-27.03]; p=0.46; I 2 =0%). Hospital length of stay was longer in the CD133 + group (n=95; MD, 2.00 days [95% CI, 0.98-3.02]; p=0.0001; I 2 =0%). Conclusion: Adjunctive CD133 + cell therapy during CABG was not associated with significant improvements in ventricular function, myocardial scar burden, arrhythmia, or mortality compared with CABG alone. Further studies are needed to better define its role in selected patient populations.
Ischemic cardiomyopathy remains a leading cause of cardiovascular mortality. Although autologous CD133⁺ progenitor cell therapy has been investigated as an adjunct to coronary artery bypass grafting (CABG), its clinical efficacy and safety remain uncertain. This systematic review and meta-analysis aimed to evaluate the efficacy and safety of autologous CD133⁺ cell therapy administered during CABG in patients with ischemic cardiomyopathy. A comprehensive search of PubMed/MEDLINE, Embase, Web of Science, Scopus, Google Scholar, and the Cochrane Library was conducted from database inception to January 2026. Eligible studies included randomized controlled trials and observational studies involving adults with ischemic cardiomyopathy in whom intraoperative administration of autologous CD133⁺ cells during CABG was compared with CABG alone. Random-effects meta-analyses were performed using maximum likelihood estimation with Hartung-Knapp adjustment. The certainty of evidence for critical and important outcomes was assessed using GRADE. Eleven studies encompassing 495 participants were included (7 RCTs, 4 cohort studies). No significant between-group difference was observed in MRI-assessed LVEF (MD − 1.34